Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway

Hematological Oncology

Volumn 32, Issue 4, 2014, Pages 197-204

  Schmeel, Frederic Carsten ^a   Schmeel, Leonard Christopher ^a   Kim, Young ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Beta catenin; Immuno therapy; Myeloma; Signaling; Wnt inhibitor; Wnt pathway

Indexed keywords

BETA CATENIN; PICEATANNOL; WNT PROTEIN; 3,3',4,5'-TETRAHYDROXYSTILBENE; PROPIDIUM IODIDE; STILBENE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FIBROBLAST CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; NONHUMAN; WNT SIGNALING PATHWAY; ANIMAL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FIBROBLAST; IC50; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BETA CATENIN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FIBROBLASTS; HUMANS; IMMUNOTHERAPY; INHIBITORY CONCENTRATION 50; MICE; MULTIPLE MYELOMA; PROPIDIUM; STILBENES; TREATMENT OUTCOME; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84914124654     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2122     Document Type: Article

References (46)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
2. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645-2654.
3. Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397-403.
4. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593.
5. Bringhen S, Avonto I, Magarotto V, Boccadoro M, Palumbo A. Investigational treatments for multiple myeloma. Expert Opin Investig Drugs 2006; 15: 1565-1582.
6. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
7. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
8. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
9. Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32.
10. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
11. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev 2006; 20: 1394-1404.
12. Kim Y, Reifenberger G, Lu D, et al. Influencing the Wnt signaling pathway in multiple myeloma. Anticancer Res 2011; 31(2): 725-730.
13. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16(13): 3797-3804.
14. Dutta-Simmons J, Zhang Y, Gorgun G, et al. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 2009; 114: 2699.
15. Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 2003; 22: 1536.
16. Sukhdeo K, Mani M, Zhang Y, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 2007; 104: 7516-7521.
17. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 2004; 101: 6122.
18. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467.
19. Ashihara E, Kawata E, Nakagawa Y, et al. {beta}-Catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 2009; 15: 2731-2738.
20. Kim Y, Gast SM, Endo T, Lu D, Carson D, Schmidt-Wolf IG. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma. Leuk Res 2012; 36(5): 598-600.
21. Kim Y, Schmidt M, Endo T, Lu D, Carson D, Schmidt-Wolf IG. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 2011; 25(6): 887-893.
22. Cantos E, Espin JC, Fernandez MJ, Oliva J, Tomas-Barberan FA. Postharvest UV-C-irradiated grapes as a potential source for producing stilbene-enriched red wines. J Agric Food Chem 2003; 51(5): 1208-1214.
23. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem 2004; 52(15): 4713-4719.
24. Ku KL, Chang PS, Cheng YC, Lien CY. Production of stilbenoids from the callus of arachis hypogaea: a novel source of the anticancer compound piceatannol. J Agric Food Chem 2005; 53(10): 3877-3881.
25. Wolter F, Clausnitzer A, Akoglu B, Stein J. Piceatannol, a natural analog of resveratrol, inhibits progression through the s phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002; 132(2): 298-302.
26. Ferrigni NR, McLaughlin JL, Powell RG, Smith CR Jr. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 1984; 47(2): 347-352.
27. Kita Y, Miura Y, Yagasaki K. Antiproliferative and anti-invasive effect of piceatannol, a polyphenol present in grapes and wine, against hepatoma AH109A cells. J Biomedicine Biotech 2012; 2012: 7 pages.672416
28. Kim EJ, Park H, Park SY, Jun JG, Park JHY. The grape component piceatannol induces apoptosis in du145 human prostate cancer cells via the activation of extrinsic and intrinsic pathways. J Med Food 2009; 12(5): 943-951.
29. Wieder T, Prokop A, Bagci B, et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 2001; 15(11): 1735-1742.
30. Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-κB activation, and apoptosis. J Immunol 2004; 173(2): 1066-1077.
31. Hsieh TC, Lin CY, Lin HY, Wu JM. AKT/mTOR as novel targets of polyphenol piceatannol possibly contributing to inhibition of proliferation of cultured prostate cancer cells. ISRN Urology 2012; 2012: 8 pages.272697
32. Ko HS, Lee HJ, Kim SH, Lee EO. Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-kappaB pathways. J Agric Food Chem 2012; 60: 4083-4089.
33. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
34. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126-3135.
35. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004; 104: 4181-4187.
36. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 99(22): 14374-14379. [Epub 2002 Oct 21].
37. Kwon GT, Jung JI, Song HR, et al. Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling. J Nutr Biochem 2012; 3: 228-238.
38. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9(1): 316-326.
39. Fowler JA, Mundy GR, Lwin ST, Edwards CM. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 2012; 72(9): 2183-2189. doi: 10.1158/0008-5472.CAN-11-2067. [Epub 2012 Feb 28]
40. Kocemba KA, Groen RW, van Andel H, et al. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One 2012; 7(2): e30359. doi: 10.1371/journal.pone.0030359. [Epub 2012 Feb 17].
41. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
42. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
43. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12(2): 131-144.
44. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12(2): 115-130.
45. Jayasooriya RG, Lee YG, Kang CH, et al. Piceatannol inhibits MMP-9-dependent invasion of tumor necrosis factor-α-stimulated DU145 cells by suppressing the Akt-mediated nuclear factor-κB pathway. Oncol Lett 2013; 5(1): 341-347.
46. Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103(8): 3175-3184.